For research use only. Not for therapeutic Use.
Certain chronic neurologic disorders, such as Parkinson’s disease, are caused by an insufficiency of the neurotransmitter dopamine secondary to the degeneration of substantia nigra dopaminergic neurons. N-<wbr></wbr>(α-<wbr></wbr>Linolenoyl) tyrosine (NALT) is a simple α-<wbr></wbr>amide conjugate between the ω-<wbr></wbr>3 essential fatty acid α-<wbr></wbr>linolenate and the amino acid tyrosine. α-<wbr></wbr>Linolenate is an important precursor to docosahexaenoic acid (DHA), a prominent brain polyunsaturated fatty acid, while tyrosine is the metabolic precursor for neuronal dopamine synthesis. NALT was prepared as a method for enhancing central nervous system (CNS) dopamine content by facilitated transport of the tyrosine precursor across the blood-<wbr></wbr>brain barrier. In experimental rat models of dopamine insufficiency, NALT increased CNS dopamine levels and exhibited an activity profile consistent with an anti-<wbr></wbr>Parkinson’s therapeutic agent.
Catalog Number | R042291 |
CAS Number | 259143-19-6 |
Synonyms | NALT |
Molecular Formula | C27H39NO4 |
Purity | ≥95% |
Storage | -20°C |
IUPAC Name | (2S)-3-(4-hydroxyphenyl)-2-[[(9Z,12Z,15Z)-octadeca-9,12,15-trienoyl]amino]propanoic acid |
InChI | InChI=1S/C27H39NO4/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-16-17-26(30)28-25(27(31)32)22-23-18-20-24(29)21-19-23/h3-4,6-7,9-10,18-21,25,29H,2,5,8,11-17,22H2,1H3,(H,28,30)(H,31,32)/b4-3-,7-6-,10-9-/t25-/m0/s1 |
InChIKey | DEQLZTQITSWABQ-GMOGWPNXSA-N |
SMILES | CCC=CCC=CCC=CCCCCCCCC(=O)NC(CC1=CC=C(C=C1)O)C(=O)O |
Reference | 1.Martin, J.B. Molecular basis of the neurodegenerative disorders. New England Journal of Medicine 340, 1970-1980 (1999). |